XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUES - Disaggregation of Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Total revenues $ 6,590 $ 6,423
U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,355 4,260
Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,202 1,336
Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 1,033 827
Total product sales    
Disaggregation of Revenue [Line Items]    
Total revenues 6,534 6,340
Total product sales | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,329 4,240
Total product sales | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,174 1,275
Total product sales | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 1,031 825
Total HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 3,707 3,650
Total HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 2,862 2,786
Total HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 550 578
Total HIV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 295 286
Biktarvy    
Disaggregation of Revenue [Line Items]    
Total revenues 2,151 1,824
Biktarvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 1,706 1,465
Biktarvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 261 216
Biktarvy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 184 143
Complera/Eviplera    
Disaggregation of Revenue [Line Items]    
Total revenues 44 63
Complera/Eviplera | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 17 25
Complera/Eviplera | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 24 34
Complera/Eviplera | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 4 4
Descovy    
Disaggregation of Revenue [Line Items]    
Total revenues 374 359
Descovy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 311 282
Descovy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 32 42
Descovy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 31 35
Genvoya    
Disaggregation of Revenue [Line Items]    
Total revenues 582 673
Genvoya | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 457 506
Genvoya | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 77 106
Genvoya | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 48 61
Odefsey    
Disaggregation of Revenue [Line Items]    
Total revenues 339 367
Odefsey | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 232 240
Odefsey | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 96 113
Odefsey | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 11 14
Stribild    
Disaggregation of Revenue [Line Items]    
Total revenues 32 46
Stribild | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 22 31
Stribild | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 8 11
Stribild | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 3 4
Truvada    
Disaggregation of Revenue [Line Items]    
Total revenues 38 135
Truvada | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 28 119
Truvada | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 4 7
Truvada | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 6 9
Revenue share - Symtuza    
Disaggregation of Revenue [Line Items]    
Total revenues 132 135
Revenue share - Symtuza | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 86 89
Revenue share - Symtuza | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 44 44
Revenue share - Symtuza | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 3 2
Other HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 14 48
Other HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 5 29
Other HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 4 5
Other HIV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 5 14
Veklury    
Disaggregation of Revenue [Line Items]    
Total revenues 1,535 1,456
Veklury | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 801 820
Veklury | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 304 388
Veklury | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 430 248
Total HCV    
Disaggregation of Revenue [Line Items]    
Total revenues 399 510
Total HCV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 199 258
Total HCV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 95 135
Total HCV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 105 117
Ledipasvir/Sofosbuvir    
Disaggregation of Revenue [Line Items]    
Total revenues 35 56
Ledipasvir/Sofosbuvir | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 13 19
Ledipasvir/Sofosbuvir | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 4 16
Ledipasvir/Sofosbuvir | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 18 21
Sofosbuvir/Velpatasvir    
Disaggregation of Revenue [Line Items]    
Total revenues 330 381
Sofosbuvir/Velpatasvir | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 162 214
Sofosbuvir/Velpatasvir | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 83 75
Sofosbuvir/Velpatasvir | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 85 92
Other HCV    
Disaggregation of Revenue [Line Items]    
Total revenues 34 73
Other HCV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 24 25
Other HCV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 8 44
Other HCV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 2 4
Total HBV/HDV    
Disaggregation of Revenue [Line Items]    
Total revenues 235 220
Total HBV/HDV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 80 81
Total HBV/HDV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 28 23
Total HBV/HDV | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 128 116
Vemlidy    
Disaggregation of Revenue [Line Items]    
Total revenues 200 181
Vemlidy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 80 77
Vemlidy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 9 8
Vemlidy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 111 96
Viread    
Disaggregation of Revenue [Line Items]    
Total revenues 23 31
Viread | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 0 4
Viread | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 6 7
Viread | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 17 20
Other HBV/HBD    
Disaggregation of Revenue [Line Items]    
Total revenues 13 8
Other HBV/HBD | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Other HBV/HBD | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 13 8
Other HBV/HBD | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Total cell therapy    
Disaggregation of Revenue [Line Items]    
Total revenues 274 191
Total cell therapy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 172 119
Total cell therapy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 92 65
Total cell therapy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 10 7
Tecartus    
Disaggregation of Revenue [Line Items]    
Total revenues 63 31
Tecartus | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 47 27
Tecartus | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 15 4
Tecartus | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 1 0
Yescarta    
Disaggregation of Revenue [Line Items]    
Total revenues 211 160
Yescarta | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 125 92
Yescarta | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 77 61
Yescarta | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 9 7
Trodelvy    
Disaggregation of Revenue [Line Items]    
Total revenues 146 72
Trodelvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 119 72
Trodelvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 25 0
Trodelvy | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 2 0
Total other    
Disaggregation of Revenue [Line Items]    
Total revenues 236 241
Total other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 94 104
Total other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 81 86
Total other | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 62 51
AmBisome    
Disaggregation of Revenue [Line Items]    
Total revenues 144 121
AmBisome | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 25 12
AmBisome | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 66 66
AmBisome | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 53 43
Letairis    
Disaggregation of Revenue [Line Items]    
Total revenues 43 54
Letairis | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 43 54
Letairis | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Letairis | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Other    
Disaggregation of Revenue [Line Items]    
Total revenues 50 66
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 26 38
Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 15 20
Other | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues 9 8
Royalty, contract and other revenues    
Disaggregation of Revenue [Line Items]    
Total revenues 56 83
Royalty, contract and other revenues | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 27 20
Royalty, contract and other revenues | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 27 61
Royalty, contract and other revenues | Other International    
Disaggregation of Revenue [Line Items]    
Total revenues $ 3 $ 2